Form 4: Rhythm Pharmaceuticals Executive Jennifer Kayden Lee Sells Shares to Cover Tax Obligations

Jennifer Kayden Lee, EVP, Head of North America at Rhythm Pharmaceuticals, sold shares of common stock on March 20, 2024, to cover withholding taxes related to vesting restricted stock units.

Summary

• On March 20, 2024, Jennifer Kayden Lee, EVP, Head of North America at Rhythm Pharmaceuticals, sold shares of the company's common stock.
• The sales were executed in two transactions at weighted average prices of $38.22 and $39.33 per share.
• A total of 9,169 shares were sold at prices ranging from $37.75 to $38.68, and 9,066 shares were sold at prices ranging from $38.75 to $39.72.
• The sales were conducted under a pre-existing Rule 10b5-1 trading plan adopted before February 27, 2023.
• The purpose of the sales was to cover withholding taxes associated with the vesting of previously reported restricted stock units.
• Following the transactions, Ms. Lee directly owns 6,852 shares of Rhythm Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing stock sales for tax purposes. It doesn't convey strong positive or negative sentiment.

Industry Context

Executive stock sales are a common occurrence, often related to compensation and tax planning. The use of a 10b5-1 plan suggests the sales were pre-planned and not based on inside information.

Stakeholder Impact

• The stock sales may have a minor impact on shareholders due to the increased supply of shares in the market, but the impact is likely to be minimal given the relatively small volume of shares sold.

Key Dates